Assessing radiation exposure and dose delivery in Y90 radioembolization for liver cancer
Official title: Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
Run by University of Tennessee · NCT03686709 · Data updated 2026-11-12
This study is testing how much radiation doctors and nurses are exposed to while using a new treatment for liver cancer that involves tiny radioactive beads, to make sure everyone stays safe during the procedure.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University of Tennessee Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Knoxville, Tennessee) |
| Status | Recruiting |
| Started | June 19, 2018 |
| Main results expected | June 18, 2019 |
| Study ends | December 31, 2019 |
| Registry record updated | September 27, 2018 |
| Trial ID | NCT03686709 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres who can tolerate additional imaging and blood draws.
✕Probably not a fit
Patients who are not candidates for Y90 radioembolization therapy or cannot tolerate additional imaging or blood draws will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the radiation exposure and dose delivery associated with the use of yttrium-90 (Y90) microspheres in treating hepatocellular carcinoma (HCC) and other metastatic liver diseases. It focuses on the safety of clinical personnel handling these radioactive materials and employs advanced dosimeter technology to measure radiation exposure. Additionally, the study will utilize a portable detector for real-time monitoring of radiation fields during the administration of Y90 microspheres. The findings aim to enhance the understanding of safety protocols and improve treatment efficacy.
Why it matters
Potential benefit: If successful, this study could improve safety protocols for healthcare workers and enhance the effectiveness of Y90 radioembolization therapy for patients with liver cancer.
How similar studies have gone: While there have been studies on radiation exposure in similar contexts, this specific approach using new dosimeter technology and real-time monitoring is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study * Must be able to schedule and tolerate additional PET/CT imaging following therapy * Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure. Exclusion Criteria: * Patients that are not candidates for Y90 radioembolization therapy * Patients that cannot tolerate additional imaging procedures following therapy * Patients that cannot tolerate the additional blood draws required for this study * Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study
Where it's running
-
University of Tennessee Medical Center
Knoxville, Tennessee, United States Recruiting
Study contacts
- Principal investigator: Dustin Osborne, PhD — University of Tennessee
- Study coordinator: Dustin Osborne, PhD
- Email: dosborne@utmck.edu
- Phone: 8653058264
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InstaSure Non-Invasive Finger-Press Test for HCC
This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer
This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)
This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.
-
GLP-1 RA plus standard treatment in first-line metastatic GI cancers
This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.